Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00414999
Status:
COMPLETED
Last Update Posted:
2007-07-30
First Post:
2006-12-20
Brief Title:
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
Sponsor:
TargeGen
Organization:
TargeGen
Study Overview
Official Title:
A Phase 1 Double-Masked Placebo-Controlled Dose-Escalation Study in Two Parts of TG100801 and a Colored Vehicle in Adult Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2007-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The formation of new blood vessels angiogenesis blood vessel leakage and inflammation contribute to the progression of the eye disease age-related macular degeneration AMD which is the leading cause of irreversible severe loss of vision in people 55 years of age and older in the developed world TG100801 is a new drug that inhibits ocular angiogenesis vascular leak and inflammation in laboratory studies and may have great utility in the treatment of diseases such as AMD
The purpose of this study is to assess the safety ocular tolerability and blood pharmacokinetics of TG100801 at escalating doses in healthy volunteers
The purpose of this study is to assess the safety ocular tolerability and blood pharmacokinetics of TG100801 at escalating doses in healthy volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None